^
Association details:
Biomarker:No biomarker
Cancer:Anal Carcinoma
Regimen:MIXE (capecitabine + mitomycin)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
06/05/2020
Excerpt:
Local RT with or without continuous infusion 5-FU/mitomycin, mitomycin/capecitabine, or 5-FU/cisplatin (category 2B) can be considered as alternative treatment options when surgical margins are inadequate.